TransMedics Group (NASDAQ:TMDX) Downgraded to “Hold” Rating by Wall Street Zen

TransMedics Group (NASDAQ:TMDX) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other research firms also recently weighed in on TMDX. Piper Sandler reiterated an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Zacks Research lowered shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Finally, Morgan Stanley increased their price target on shares of TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Six equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $144.25.

TransMedics Group Stock Performance

Shares of TMDX opened at $133.98 on Friday. TransMedics Group has a 1 year low of $62.07 and a 1 year high of $156.00. The company’s 50 day simple moving average is $134.30 and its 200 day simple moving average is $123.60. The company has a market capitalization of $4.58 billion, a price-to-earnings ratio of 54.24 and a beta of 2.03. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The company had revenue of $143.82 million during the quarter, compared to the consensus estimate of $145.33 million. During the same period in the previous year, the firm posted $0.12 EPS. TransMedics Group’s revenue was up 32.2% on a year-over-year basis. On average, sell-side analysts predict that TransMedics Group will post 1 EPS for the current year.

Insider Transactions at TransMedics Group

In related news, insider Anil P. Ranganath sold 3,000 shares of the stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $145.22, for a total value of $435,660.00. Following the completion of the sale, the insider directly owned 13,955 shares in the company, valued at approximately $2,026,545.10. This represents a 17.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Gerardo Hernandez sold 920 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $139.62, for a total value of $128,450.40. Following the transaction, the chief financial officer owned 15,064 shares in the company, valued at approximately $2,103,235.68. This represents a 5.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 8,920 shares of company stock valued at $1,257,310 over the last 90 days. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On TransMedics Group

Several hedge funds have recently modified their holdings of TMDX. Vanguard Group Inc. boosted its holdings in TransMedics Group by 0.3% in the 3rd quarter. Vanguard Group Inc. now owns 3,605,607 shares of the company’s stock worth $404,549,000 after acquiring an additional 9,650 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of TransMedics Group by 11.9% during the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company’s stock worth $119,997,000 after purchasing an additional 113,817 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of TransMedics Group by 1.4% in the second quarter. Geode Capital Management LLC now owns 804,650 shares of the company’s stock valued at $107,845,000 after purchasing an additional 11,241 shares during the period. Two Sigma Investments LP grew its holdings in TransMedics Group by 54.2% during the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company’s stock valued at $71,291,000 after purchasing an additional 223,409 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in TransMedics Group by 258.7% during the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company’s stock worth $73,275,000 after buying an additional 394,340 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.